Showing results (71-80 of 89) with videos related to
Sort By:
Pageof 9
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemiaSusan O'Brien, Gary Schiller, John Lister, et al.Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in LeukemiaMichael Andreeff, Kevin R Kelly, Karen Yee, et al.Transplantation and Cellular Therapy|November 10, 2025
Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular TherapyC Arianne Buchan, Gerard Agbayani, Katrina Hueniken, et al.The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.American Journal of Hematology|August 30, 2023
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO studyGiovanni Paolo Maria Zambrotta, Franck E Nicolini, Sarit Assouline, et al.Pageof 9